Hematological parameters relevant to AOC
| . | Nonbleeding term pregnant controls (N = 20) . | AOC (N = 12) . | Severe PPH without AOC (N = 21) . | AOC vs non-AOC P value . |
|---|---|---|---|---|
| Prohemostatic factors | ||||
| FV, IU/dL | 109.4 (97.9-121.0) | 50.1 (32.2-77.1) | 81.7 (63.5-115.1) | .009 |
| Med (IQR) range | 74.4-141.0 | 15.5-101.6 | 15.7-174 | |
| FVIII, IU/dL | 181.8 (147.1-244.6) | 159.4 (58.6-314.5) | 296.1 (198.9-378.7) | .06 |
| 108.4-398.2 | 49.8-439.5 | 97.2-908.4 | ||
| FVIII/VWF ratio | 0.6 (0.5-1.0) | 0.28 (0.19-0.44) | 0.81 (0.60-1.07) | .0005 |
| Med (IQR) range | 0.4-1.4 | 0.12-0.74 | 0.28-1.73 | |
| FII, IU/dL | 145.3 (131.7-150.2) | 96 (71-119) | 109.3 (89.4-123.9) | .23 |
| Med (IQR) range | 123.6-172.2 | 61-161 | 32.4-155.3 | |
| FX, IU/dL | 159.0 (139.7-177.3) | 98.0 (78.6-116.5) | 106.9 (93.7-153.1) | .32 |
| Med (IQR) range | 121.6-238.2 | 61.5-182.8 | 31.2-203.2 | |
| Endogenous thrombin potential, nM/min | 2067 (1944-2367) | 2089 (1886-2379) | 2040 (1815-2423) | .86 |
| Med (IQR) range | 1273-3008 | 1223-3808 | 1015-3006 | |
| Fibrinolytic parameters | ||||
| Plasmin generation, pM/s | 0.35 (0.32-0.52) | 1.95 (1.09-2.49) | 0.48 (0.39-0.86) | .0002 |
| Med (IQR) range | 0.07-0.66 | 0.51-3.0 | 0.02-1.28 | |
| PAI-1 antigen, ng/mL | 52.9 (41.9-52.9) | 30.0 (16.0-77.6) | 23.9 (17.1-46.9) | .89 |
| Med (IQR) range | 21.6-88.9 | 2.1-326 | 4.9-128.3 | |
| PAI-1 activity, ng/mL | 164.6 (126.5-227.6) | 73.6 (18.9-456.7) | 86.7 (21.6-220.4) | .87 |
| Med (IQR) range | 54.3-327.6 | 4.9-914.6 | 1.5-630.8 | |
| PAI-2 antigen, ng/mL | 133.9 (83.6-198.1) | 92.8 (67.5-179.0) | 124.0 (88.2-300.1) | .23 |
| Med (IQR) range | 57.4-329.2 | 46.9-245.5 | 18.1-441.8 | |
| uPA antigen, ng/mL | 1.9 (1.6-2.1) | 1.0 (0.7-1.3) | 1.2 (0.92-1.38) | .13 |
| Med (IQR) range | 1-2.8 | 0.53-1.66 | 0.41-2.94 | |
| tPA antigen, ng/mL | 1.4 (1.0-1.9) | 1.8 (1.3-3.0) | 1.17 (0.92-1.38) | .53 |
| Med (IQR) range | 0.5-6.0 | 0.4-12.5 | 0.41-2.94 | |
| . | Nonbleeding term pregnant controls (N = 20) . | AOC (N = 12) . | Severe PPH without AOC (N = 21) . | AOC vs non-AOC P value . |
|---|---|---|---|---|
| Prohemostatic factors | ||||
| FV, IU/dL | 109.4 (97.9-121.0) | 50.1 (32.2-77.1) | 81.7 (63.5-115.1) | .009 |
| Med (IQR) range | 74.4-141.0 | 15.5-101.6 | 15.7-174 | |
| FVIII, IU/dL | 181.8 (147.1-244.6) | 159.4 (58.6-314.5) | 296.1 (198.9-378.7) | .06 |
| 108.4-398.2 | 49.8-439.5 | 97.2-908.4 | ||
| FVIII/VWF ratio | 0.6 (0.5-1.0) | 0.28 (0.19-0.44) | 0.81 (0.60-1.07) | .0005 |
| Med (IQR) range | 0.4-1.4 | 0.12-0.74 | 0.28-1.73 | |
| FII, IU/dL | 145.3 (131.7-150.2) | 96 (71-119) | 109.3 (89.4-123.9) | .23 |
| Med (IQR) range | 123.6-172.2 | 61-161 | 32.4-155.3 | |
| FX, IU/dL | 159.0 (139.7-177.3) | 98.0 (78.6-116.5) | 106.9 (93.7-153.1) | .32 |
| Med (IQR) range | 121.6-238.2 | 61.5-182.8 | 31.2-203.2 | |
| Endogenous thrombin potential, nM/min | 2067 (1944-2367) | 2089 (1886-2379) | 2040 (1815-2423) | .86 |
| Med (IQR) range | 1273-3008 | 1223-3808 | 1015-3006 | |
| Fibrinolytic parameters | ||||
| Plasmin generation, pM/s | 0.35 (0.32-0.52) | 1.95 (1.09-2.49) | 0.48 (0.39-0.86) | .0002 |
| Med (IQR) range | 0.07-0.66 | 0.51-3.0 | 0.02-1.28 | |
| PAI-1 antigen, ng/mL | 52.9 (41.9-52.9) | 30.0 (16.0-77.6) | 23.9 (17.1-46.9) | .89 |
| Med (IQR) range | 21.6-88.9 | 2.1-326 | 4.9-128.3 | |
| PAI-1 activity, ng/mL | 164.6 (126.5-227.6) | 73.6 (18.9-456.7) | 86.7 (21.6-220.4) | .87 |
| Med (IQR) range | 54.3-327.6 | 4.9-914.6 | 1.5-630.8 | |
| PAI-2 antigen, ng/mL | 133.9 (83.6-198.1) | 92.8 (67.5-179.0) | 124.0 (88.2-300.1) | .23 |
| Med (IQR) range | 57.4-329.2 | 46.9-245.5 | 18.1-441.8 | |
| uPA antigen, ng/mL | 1.9 (1.6-2.1) | 1.0 (0.7-1.3) | 1.2 (0.92-1.38) | .13 |
| Med (IQR) range | 1-2.8 | 0.53-1.66 | 0.41-2.94 | |
| tPA antigen, ng/mL | 1.4 (1.0-1.9) | 1.8 (1.3-3.0) | 1.17 (0.92-1.38) | .53 |
| Med (IQR) range | 0.5-6.0 | 0.4-12.5 | 0.41-2.94 | |
Med (IQR), median (interquartile range).
If >1 sample was available from a patient, the samples at the time of the highest PAP were analyzed.